FDA OKs First Rifabutin-Based H Pylori Therapy Talicia FDA OKs First Rifabutin-Based H Pylori Therapy Talicia

Talicia combines omeprazole, amoxicillin, and rifabutin and is designed to address growing bacterial resistance to standard clarithromycin-based H pylori therapy.FDA Approvals
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Alert Source Type: news

Related Links:

Authors: Yun J, Wu Z, Qi G, Han T, Zhang D Abstract INTRODUCTION: More attention has been paid to the eradication therapy of H. pylori with the enhancement of health awareness of patients. However, the increasing antibiotic resistance of H. pylori, due to the wide use and abuse of antibiotics, has become a critical factor affecting the efficacy of eradication. To effectively improve the eradication rate of H. pylori, high-dose amoxicillin-proton pump inhibitor (PPI) dual therapy has recently become one of the hot issues. AREAS COVERED: The authors review the schemes and efficacy of high-dose amoxicillin-PPI dua...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
Authors: He M, Zheng Y, Ma A, Zhang C, Yu Y, Wang H, Chen Y, Xiang M, Tao K, Shen J Abstract The present study aimed to investigate the potential association between Helicobacter pylori (a H. pylori) positive state and chronic cough. A clinical observational study with systematic analysis was performed, including 278 patients with complaints of chronic cough and 148 healthy controls. a H. pylori positive state was present in 61.2% of the patients in the chronic cough group and 68.9% in the chronic refractory cough group, as opposed to 43.9% in the control group. There was a significant improvement in 65.5% of the p...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
Conclusion: There was a strong and significant association between CU and H. pylori infection. We recommend investigating for H. pylori in all cases of CU and conducting further trials on H. pylori eradication. PMID: 32952551 [PubMed]
Source: Dermatology Research and Practice - Category: Dermatology Tags: Dermatol Res Pract Source Type: research
Condition:   Helicobacter Pylori Eradication Interventions:   Drug: Minocycline hydrochloride capsule;   Drug: Clarithromycin Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Objectives: The aim of the study was to assess clinical presentation, endoscopic findings, antibiotic susceptibility and treatment success of Helicobacter pylori (H. pylori) infected pediatric patients. Methods: Between 2013 and 2016, 23 pediatric hospitals from 17 countries prospectively submitted data on consecutive H. pylori-infected (culture positive) patients to the EuroPedHP-Registry. Results: Of 1333 patients recruited (55.1% girls, median age 12.6 years), 1168 (87.6%) were therapy naïve (group A) and 165 (12.4%) had failed treatment (group B). Patients resided in North/Western (29.6%), Southern (34.1%)...
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Gastroenterology Source Type: research
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Future Microbiology,Volume 15, Issue 12, Page 1131-1137, August 2020.
Source: Future Microbiology - Category: Microbiology Authors: Source Type: research
Future Microbiology,Volume 15, Issue 12, Page 1185-1196, August 2020.
Source: Future Microbiology - Category: Microbiology Authors: Source Type: research
Conclusions Diagnostic limitations of M-NBI depend on four distinct histological characteristics. For accurate diagnosis of M-NBI-DLLs, it may be necessary to fully understand endoscopic features of these lesions using white light imaging and M-NBI based on these histological characteristics and to take a precise biopsy. [...] Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyArticle in Thieme eJournals: Table of contents  |  Abstract  |  open access Full text
Source: Endoscopy International Open - Category: Gastroenterology Authors: Tags: Original article Source Type: research
We report that cholesteryl glucosides in H. pylori activate innate immunity through C-type lectin receptors (CLRs). Cholesteryl acyl α-glucoside (αCAG) was identified as a ligand for Mincle (Clec4e). Upon H. pylori infection, T cell responses and gastritis were ameliorated in Mincle-deficient mice, although bacterial numbers were comparable.Thus the cholesteryl lipid–CLR axis exacerbates H. pylori-induced gastric inflammation with limited contribution to protective immunity.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
More News: Amoxicillin | Biaxin | Clarithromycin | Helicobacter Pylori | Infectious Diseases | Intensive Care | Omeprazole | Prilosec